2003 JUL 1 - (NewsRx.com & NewsRx.net) -- Genta, Inc., (GNTA) announced the presentation of results from a clinical trial using the company's lead anticancer compound, Genasense (oblimersen sodium), plus chemotherapy for treatment of patients with small-cell lung cancer (SCLC).
The data were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) by Charles Rudin, MD, PhD, assistant professor of medicine at the University of Chicago, who was the principal investigator.
Supported by these results, Genta also announced initiation of a new, randomized trial in previously untreated patients with extensive-stage SCLC.
The …
No comments:
Post a Comment